InvestorsHub Logo
Followers 21
Posts 1676
Boards Moderated 0
Alias Born 07/09/2005

Re: rebelwithacause post# 172

Sunday, 12/10/2017 5:46:53 PM

Sunday, December 10, 2017 5:46:53 PM

Post# of 788
Well worth a purchase still at this low valuation.

ASH 2017 ANALYST EVENT
Sunday, December 10, 2017 8:15 p.m. ET
Webcast Presentation
http://phx.corporate-ir.net/phoenix.zhtml?c=250749&p=irol-EventDetails&EventId=5266482
Event Details
Title
ASH 2017 Analyst Event
Date / Time
12/10/17 8:15 p.m. ET

Verastem Announces Clinical Data from the Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Sun December 10, 2017 4:30 PM|Business Wire|About: VSTM
https://seekingalpha.com/pr/17022759-verastem-announces-clinical-data-pivotal-phase-3-duo-study-duvelisib-significantly-improves
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VSTM News